🇺🇸 FDA

Company profile · Sponsor

Acadia

Acadia Pharmaceuticals B.V.

ACAD · NYSE pharma SAN DIEGO, CA, EU
Pipeline
24
Drugs
2
Patents
8

Quick answer

Acadia (ACAD) is a pharma company. headquartered in SAN DIEGO, CA, EU. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 2 drugs, and 8 patents to this profile..

Company facts

Ticker ACAD
Exchange NYSE
Company type pharma
Headquarters SAN DIEGO, CA, EU
SEC CIK 0001070494

Pipeline (24)

Search pipeline →

  1. ACP-204

    Acadia

    Lewy Body Dementia Psychosis

    phase 3 small molecule active

    2 trials

  2. ACP-204

    Acadia

    Alzheimer's Disease Psychosis

    phase 3 small molecule active

    2 trials

  3. Carbetocin

    Acadia

    Hyperphagia in Prader-Willi Syndrome

    phase 3 small molecule active

    2 trials

  4. Pimavanserin

    Acadia

    Neuropsychiatric Symptoms Related to Neurodegenerative Disease

    phase 3 small molecule completed

    2 trials

  5. Pimavanserin

    Acadia

    Adjunctive Treatment of Major Depressive Disorder

    phase 3 small molecule terminated

    3 trials

  6. Pimavanserin

    Acadia

    Schizophrenia

    phase 3 small molecule completed

    4 trials

  7. Pimavanserin

    Acadia

    Irritability Associated With Autism Spectrum Disorder

    phase 3 small molecule completed

    2 trials

  8. Pimavanserin tartrate (ACP-103)

    Acadia

    Parkinson's Disease Psychosis

    phase 3 small molecule completed

    4 trials

  9. Placebo

    Acadia

    Dementia-related Psychosis

    phase 3 small molecule completed

    1 trial

  10. Trofinetide

    Acadia

    Rett Syndrome

    phase 3 small molecule completed

    4 trials

  11. pimavanserin tartrate

    Acadia

    Parkinson's Disease Psychosis

    phase 3 small molecule completed

    1 trial

  12. ACP-044 Dose A

    Acadia

    Acute Postoperative Pain

    phase 2 small molecule completed

    1 trial

  13. ACP-044 Dose A

    Acadia

    Osteoarthritis Pain

    phase 2 small molecule terminated

    1 trial

  14. ACP-103

    Acadia

    Hallucinations

    phase 2 small molecule completed

    1 trial

  15. ACP-103

    Acadia

    Schizophrenia

    phase 2 small molecule completed

    1 trial

  16. ACP-104

    Acadia

    Schizophrenia

    phase 2 small molecule completed

    2 trials

  17. ACP-211

    Acadia

    Major Depressive Disorder (MDD)

    phase 2 small molecule active

    1 trial

  18. Active drug: pimavanserin 17mg (2 strength tablets)

    Acadia

    Parkinson Disease

    phase 2 small molecule completed

    1 trial

  19. Pimavanserin

    Acadia

    Parkinson's Disease

    phase 2 small molecule terminated

    1 trial

  20. Pimavanserin

    Acadia

    Agitation and Aggression in Alzheimer's Disease

    phase 2 small molecule completed

    1 trial

  21. Pimavanserin

    Acadia

    Treatment of Depression in Adults With Parkinson's Disease (PD)

    phase 2 small molecule completed

    1 trial

  22. Pimavanserin 34 mg

    Acadia

    Agitation and Aggression in Alzheimer's Disease

    phase 2 small molecule terminated

    1 trial

  23. Pimavanserin 34 mg

    Acadia

    Intermittent Explosive Disorder

    phase 2 small molecule active

    1 trial

  24. Pimavanserin 34 milligrams (MG) [Nuplazid]

    Acadia

    Schizophrenia

    phase 2 small molecule terminated

    1 trial

Drugs (2)

Search drugs →

  1. pimavanserin tartrate

    NUPLAZID

    ORAL approved

  2. trofinetide

    DAYBU

    ORAL approved

    N07XX

Patents (8)

Search patents →

  1. US 11844764

    Agitation process for preparing a carbetocin drug product

    Expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11827600

    Crystalline forms of trofinetide

    Expires Mon Nov 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11464768

    Pimavanserin alone or in combination for use in the treatment of Alzheimer's disease psychosis

    Expires Mon Oct 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11452721

    Formulations of pimavanserin

    Expires Mon Sep 22 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11191757

    Combination of pimavanserin and cytochrome P450 modulators

    Expires Mon Dec 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11161826

    Manufacturing methods and polymorphs of a thiazoline anti-hyperalgesic agent

    Expires Mon Oct 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11135211

    Pimavanserin for treating impulse control disorder

    Expires Mon Sep 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11091473

    Compounds for pain treatment, compositions comprising same, and methods of using same

    Expires Mon Aug 12 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Acadia?

Acadia (ACAD) is a pharma company. headquartered in SAN DIEGO, CA, EU. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 2 drugs, and 8 patents to this profile..

What pipeline programs does Acadia sponsor?

We track 24 ClinicalTrials.gov-linked programs for Acadia, including ACP-204 and 23 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Acadia company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.